Quantbot Technologies LP Acquires Shares of 66,443 Haleon plc (NYSE:HLN)

Quantbot Technologies LP acquired a new stake in shares of Haleon plc (NYSE:HLN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 66,443 shares of the company's stock, valued at approximately $634,000.

A number of other hedge funds have also recently bought and sold shares of the company. FMR LLC lifted its holdings in shares of Haleon by 5.8% during the 3rd quarter. FMR LLC now owns 104,918,269 shares of the company's stock worth $1,110,035,000 after acquiring an additional 5,768,117 shares during the period. Raymond James Financial Inc. acquired a new position in Haleon during the fourth quarter worth approximately $42,193,000. Bank Julius Baer & Co. Ltd Zurich purchased a new position in Haleon during the fourth quarter worth approximately $39,628,000. Wellington Management Group LLP boosted its holdings in shares of Haleon by 49.9% in the 3rd quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company's stock valued at $96,833,000 after purchasing an additional 3,046,841 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Haleon by 25.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company's stock valued at $53,791,000 after buying an additional 1,026,939 shares during the period. Institutional investors and hedge funds own 6.67% of the company's stock.

Haleon Stock Up 0.3 %

Shares of NYSE HLN traded up $0.04 on Monday, hitting $10.28. The company had a trading volume of 11,537,269 shares, compared to its average volume of 6,575,182. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a 12-month low of $7.99 and a 12-month high of $10.80. The firm has a market capitalization of $46.52 billion, a P/E ratio of 30.22, a PEG ratio of 2.82 and a beta of 0.25. The business has a 50 day moving average of $9.96 and a two-hundred day moving average of $9.87.

Remove Ads

Haleon (NYSE:HLN - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The firm had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.38 billion. As a group, equities research analysts forecast that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The company also recently declared a -- dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be issued a dividend of $0.1166 per share. This represents a yield of 1.6%. This is a positive change from Haleon's previous -- dividend of $0.05. The ex-dividend date is Friday, April 25th. Haleon's dividend payout ratio (DPR) is presently 58.97%.

Analyst Ratings Changes

Several research analysts recently weighed in on HLN shares. Hsbc Global Res lowered Haleon from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Sanford C. Bernstein lowered Haleon from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Haleon in a research note on Monday, March 3rd. HSBC reissued a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Finally, Morgan Stanley cut shares of Haleon from an "overweight" rating to an "equal weight" rating in a research report on Friday, January 10th. Six equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Haleon presently has an average rating of "Hold" and a consensus target price of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.